For decades, oncology has pursued the ‘magic bullet,’ precision therapies that selectively eradicate tumors while sparing healthy tissue. Antibody-drug conjugates (ADCs) are among the closest realizations of that vision. Yet as the pipeline saturates, a new reality is emerging – clinical superiority is no longer enough to differentiate.

At BioVid, our analysis of the ADC landscape suggests that an asset’s trajectory is determined by how the interplay of antibody, linker, and payload shapes the oncologist’s mental model of the drug.

The question for oncology development & commercialization is more than “Does it work?”

The real question is “How will it be categorized in the heat of clinical decision-making?”

ADC Strategic Pivot: From Design to Experience

The historical view of ADCs as “toxic payloads on a string” is obsolete. Success now hinges on how molecular engineering translates into a predictable – and manageable – clinical experience.

Consider the “Bystander Effect.” The shift from “hit what you see” to “clear what surrounds it” has expanded addressable populations in heterogeneous tumors. However, this biological advancement introduces a commercial trade-off: it shifts the oncologist’s perception of the drug from a “surgical-targeted strike” toward something more “chemo-adjacent.”

When an asset’s toxicity profile begins to mirror traditional chemotherapy, the behavioral barriers to adoption rise, unless efficacy clearly exceeds existing standards.

ADC Archetype Trap

We see ADCs falling into distinct strategic archetypes – even when they share the same molecular target. These archetypes dictate how oncologists interpret safety signals, where they place the drug in a sequence, and how they perceive its value relative to competitors.

The risk for many brands is a misalignment between clinical intent and oncologist categorization. If your asset is designed for precision but is mentally categorized by the market as a “delivery mechanism for broader cytotoxic exposure,” your launch strategy is built on a fault line.

Winning in a Saturated Market

ADC strategies are often anchored in mechanistic data yet fall short by underestimating how oncologists actually make decisions, where risk tolerance, legacy treatment heuristics, and the simplification of complex data ultimately govern uptake.

The BioVid Perspective

We help oncology leaders navigate the “categorization risk” that often separates a blockbuster from a niche player. By integrating our proprietary ADC archetype framework with a deep behavioral science lens, we provide the clarity needed to align clinical design with commercial reality.

We partner with oncology teams to shape commercial opportunities:

• Early Development: Identify how different design profiles are likely to be experienced clinically, informing target product profiles, comparator selection, and trial endpoints.
• Clinical Readout & Positioning: Translate efficacy and safety signals into clear, differentiated narratives that align with how oncologists categorize therapies (e.g., targeted vs. chemo-adjacent).
• Segmentation & Forecasting: Move beyond target-based segmentation to incorporate tolerability expectations, risk tolerance, and treatment philosophy, critical for predicting adoption.
• Competitive Strategy: Anticipate how seemingly similar assets will be mentally and clinically separated in-market, and where mispositioning creates vulnerability.

Our archetype framework is predictive of how assets are likely to be used, valued, and differentiated in practice.

When multiple ADCs can share a target, the winners will shape how their design is experienced, closing the gap between clinical intent and clinical perception.

Email info@biovid.com to find out where the categorization gap lives for your assets.